1. Scrip
  2. >>Business
  3. >>Financing

Be Bio’s New $130m Raise Will Advance B-Cell Therapies Toward The Clinic

 
• By Joseph Haas

Biotech is developing engineered B-cell therapeutics for rare diseases and cancer. They should offer greater duration and better tolerability than T-cell therapies, the company claims.

B cells
Be Bio aims to bring engineered b-cell therapies to cancer and rare disease patients • Source: Alamy

Be Biopharma has raised a $130m series B financing from new and existing investors to bring what it describes as a novel type of cell therapy – Engineered B Cell Medicines (BeCM) – closer to the clinic in oncology and rare diseases. While not offering specifics on timelines or indications, CEO Joanne Smith-Farrell suggested that one of the company’s early focuses is on improving upon current enzyme replacement therapies such as Sanofi’s Fabrazyme (agalsidase beta) or Takeda Pharmaceutical Co. Ltd.’s Vpriv (velaglucerase alfa).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.

Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings

 
• By Mandy Jackson

There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.

Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives Rise

 
• By Mandy Jackson

Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.

More from Business

Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

 
• By Jung Won Shin

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By Joseph Haas

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.